A Phase 4 interventional study of vildagliptin and metformin (combination) and glimepiride in Type 2 Diabetes and Hypoglycemia, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.
Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 92nd largest by enrollment of the 118 interventional ones that give a count, is one of 4 that started in 2014, is one of 43 in phase 4, and was the 102nd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 65 · Phase 4 43
First in 2003; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 162 across the 118 interventional studies. Of the 113 that completed or were terminated, 13 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 119 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
122 studies in Diabetes Mellitus, Type 2 by Novartis: none open now, none under way, none of them phase 3. Of 121 finished, 27 (22%) have results posted.
Among the 122 studies in Diabetes Mellitus, Type 2 by Novartis, this one is the 95th largest by enrollment of the 121 interventional ones that give a count, is the only one that started in 2014, is one of 30 in phase 4, and was the 116th registered.
Novartis’s Diabetes Mellitus, Type 2 studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 122 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
Drug: vildagliptin and metformin (combination)
Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
Drug: glimepiride · Drug: Metformin
Drug pages: Vildagliptin · Metformin
vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)
Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement.
Time frame: Week 12
Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)
Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible. CONGA is calculated in the conventional way with the formula √tқΣt = t1 (Dt -Ď2) / қ - 1, Ď = tқ Σ Dt t = t1 / қ, Dt = Gt-Gt-m (where қ = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period.
Time frame: Week 12
Glycemic Variability Measured by Total Standard Deviation (TSD)
Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept. TSD is calculated conventionally with the formula σ = √Σ (Xi - ῦ) 2 / N (where Xi represents each of the values, ῦ represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement.
Time frame: Week 12
Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12
Time frame: Screening visit , 12 weeks of treatment
Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline
Time frame: baseline, 12 weeks of treatment
Number of Patients With Incidence of Hypoglycemia
Hypoglycemia defined as Glycemia \< 70 mg/dl
Time frame: 12 weeks
Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment
MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients.
Time frame: 12 weeks
Number of Patients With Any Adverse Events, Serious Adverse Events and Death
Time frame: 12 weeks
| Milestone | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Started | 20 | 20 |
| Completed | 18 | 17 |
| Not completed | 2 | 3 |
| Withdrew: Failure to comply with an eligibility | 0 | 1 |
| Withdrew: Ingestion of drugs not allowed in study | 0 | 1 |
| Withdrew: Incorrect medication administration | 1 | 0 |
| Withdrew: Mis-randomization | 1 | 1 |
Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement.
| mg/dL | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE) | 6.68 ± 1.48 | 6.23 ± 1.08 |
Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible. CONGA is calculated in the conventional way with the formula √tқΣt = t1 (Dt -Ď2) / қ - 1, Ď = tқ Σ Dt t = t1 / қ, Dt = Gt-Gt-m (where қ = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period.
| mg/dL | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA) | 2.92 ± 0.93 | 3.01 ± 1.10 |
Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept. TSD is calculated conventionally with the formula σ = √Σ (Xi - ῦ) 2 / N (where Xi represents each of the values, ῦ represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement.
| mg/dL | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Glycemic Variability Measured by Total Standard Deviation (TSD) | 1.36 ± 0.40 | 1.40 ± 0.42 |
| percentage of patients | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12 | 100.0 | 100.0 |
| Percentage of glycosylated haemoglobin | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline | 1.92 ± 1.1 | 2.28 ± 0.79 |
Hypoglycemia defined as Glycemia \< 70 mg/dl
| Patients | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Number of Patients With Incidence of Hypoglycemia | 1 | 4 |
MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients.
| mg/dL | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment | 5.23 ± NA | 5.53 ± 0.82 |
| Patients | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| Any adverse events (serious and non-serious) | 9 | 13 |
| Serious Adverse Events | 0 | 1 |
| Death | 0 | 0 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vildagliptin and Metformin | — | 0/20 (0%) | 9/20 (45%) |
| Glimepiride and Metformin | — | 1/20 (5%) | 13/20 (65%) |
| Event | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| ErysipelasInfections and infestations | 0/20 | 1/20 |
| Event | Vildagliptin and Metformin | Glimepiride and Metformin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 1/20 | 5/20 |
| Influenza like illnessGeneral disorders | 3/20 | 1/20 |
| TremorNervous system disorders | 0/20 | 3/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/20 | 2/20 |
| HeadacheNervous system disorders | 2/20 | 1/20 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/20 | 2/20 |
| PalpitationsCardiac disorders | 0/20 | 1/20 |
| Ear painEar and labyrinth disorders | 1/20 | 0/20 |
| VertigoEar and labyrinth disorders | 1/20 | 0/20 |
| CataractEye disorders | 0/20 | 1/20 |
Randomized set
| Age, Continuous(Years) | Vildagliptin and Metformin | Glimepiride and Metformin | Total |
|---|---|---|---|
| Mean | 56.74 ± 10.58 | 55.70 ± 11.51 | 56.25 ± 10.92 |
| Sex: Female, Male(Participants) | Vildagliptin and Metformin | Glimepiride and Metformin | Total |
|---|---|---|---|
| Female | 15 | 8 | 23 |
| Male | 5 | 12 | 17 |
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2014 to primary completion in Feb 2016, 25 months.
Results were first posted in Jul 2017, 1 year 4 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 25 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vildagliptin · Metformin · Glimepiride